SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SCIO Scios Inc.
SCIO 0.010000.0%Aug 19 5:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (1356)5/25/2001 9:01:22 AM
From: Ian@SI  Read Replies (1) of 1477
 
SCIO halted until after AC results...

Trading in Scios Stock Will Be Halted During FDA Advisory Committee
Meeting TodayNatrecor to Be Reviewed by Cardiovascular and Renal Drugs Advisory
Committee

SUNNYVALE, Calif., May 25, 2001 /PRNewswire via COMTEX/ -- Scios Inc. (Nasdaq:
SCIO) announced that Nasdaq has halted trading of Scios common stock today,
Friday, May 25, 2001. The trading halt is due to the review of the Natrecor(R)
(nesiritide) New Drug Application by the Cardiovascular and Renal Drugs Advisory
Committee to the U.S. Food and Drug Administration (FDA). Natrecor is currently
under FDA review for the treatment of acute congestive heart failure. The FDA is
expected to complete its review of the Natrecor application by July of 2001.

Following today's Advisory Committee review, Scios will host a conference call
and webcast to discuss the results of the meeting. The conference call and
webcast will begin at 6:00 p.m. (EDT). The webcast will be available on Scios'
Web site at sciosinc.com. The conference call dial-in will be 800-314-7867.

A replay of both the conference call and webcast will be available through June
1, 2001. The replay dial-in number will be 888-203-1112, confirmation code
593777.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext